24 Jan 05
For people with migraine, today’s world is a better world than the one their parents knew. The last 15 years have seen major advances, giving us not only a much clearer understanding of the disorder but also considerably more effective therapies. Treatments exist that – if made available and used in the right way – can substantially relieve the majority of people affected by migraine.
21 Jan 05
The increasing incidence of surgical site infections (SSIs) among hospital patients in Europe has led to a call to action for cost-effective preventative measures to be put in place by hospitals, to help minimize the risk of infection and the cost impact on healthcare systems. A consensus paper, developed by a number of leading healthcare experts in Europe and published today in the International Wound Journal, indicates the scale of the problem and the estimated financial impact on the health
Wound Healing Research Unit
17 Jan 05
Epilepsy is a common condition in the UK, with an incidence of approximately 80 cases per 100,000 population per year, and a prevalence of 5–10 cases per 1000. Yet, despite this high prevalence, it remains a stigmatising condition, with occupational and social disadvantages imposed on the individual. Epilepsy is difficult to diagnose, requiring a detailed history, and is complex to manage.
Csf Medical Communications
17 Jan 05
Knowledge will be pooled and ideas investigated through focused discussion topics:
* What approach to take to target validation?
* Establishing the true impact of off-target effects
* Unravelling the different pathways
* What can delivery systems achieve?
* What are the pros and cons of different chemical modification?
* Addressing pharmacokinetics and modification issues for each disease
What do I need for clinical testing of an siRNA compound?
17 Jan 05
It is estimated that there are more than 38 million people in the seven major markets with diabetes and this figure is set to rise to 50 million in 2012. However, despite this vast potential patient population, low diagnosis rates, the chronic nature of the disease, the need for combination therapy, the lack of an oral antidiabetic agent offering effective long-term therapy and the association of injectable therapies with poor patient compliance mean that a broad spectrum of unmet needs exists.
13 Jan 05
Morgan Levy (formally E-Focus Resourcing) has pleasure in announcing that we have re-branded to Morgan Levy with effect from January 2005.
GARY M BRITNELL
04 Jan 05
The development of dendritic cell vaccines to fight cancer is an attractive therapeutic approach. Usually this strategy involves pre-pulsing dendritic cells with cancer antigen and maturing them ex vivo prior to administering them to patients. Limitations to this approach include the cumbersome nature of antigen loading and maturation and the limited immunogenicity of the cells. The company BioVEX have successfully developed viruses to load dendritic cells with antigen. Researchers from Baylor h
20 Dec 04
The outlook for hepatocellular carcinoma (HCC) sufferers is bleak - current medication has a five-year survival rate for those with liver cancer of less than 5% in the developed world and even lower in developing countries. However, patients in trials of a new drug called Sorafenib have seen their survival times double. Datamonitor's Dr Lorna Fern investigates...
15 Dec 04
Despite the advances made in healthcare there remains a startling amount of the world’s population that is unable to gain access to even the most basic services and treatments. This is an issue that has attracted considerable media coverage and represents a challenge for all those involved in healthcare to overcome.
Dr Faiz Kermani
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.